Lab focus: Therapeutically targeting the ubiquitin system

Ubiquitin (Ub) is a small protein found in almost all tissues in humans that helps to regulate cellular processes. Deregulated Ub signalling has been linked to a number of diseases.

The Feltham laboratory focuses on understanding how Ub signalling is deregulated in cancer and inflammatory disease to aid in the development of new therapies and the identification of diagnostic biomarkers.

Research interest 

The Feltham laboratory specialises in all aspects of E3 ligase biology, and seeks to define new roles for these proteins in disease-associated signaling pathways.

Our research focuses on the identification and characterisation of disease-associated E3 ubiquitin ligases, and assesses the potential of targeting these proteins therapeutically for the treatment of cancer and inflammatory-driven disease. 

A major focus of the Feltham laboratory is also to exploit the degradative functions of select E3 ubiquitin ligases using proteolysis targeting chimaera (PROTAC) technology to remove disease-causing proteins that, until now, have been considered ‘undruggable'.